Objective
In Europe, as observed in other parts of the world, cardiovascular (CV) diseases represent the leading cause of death. In the European Union, CV deaths account for 1.9 million deaths per year, and treatment costs for CV disease amount to an estimated 200 billion Euros per year. CV diseases encompass various pathologies that can lead to a progressive loss of cardiac contractile function and the clinical syndrome of heart failure (HF), including ischemic heart disease and myocardial infarction. Drug therapy can successfully slow down the progression of HF and reduce mortality, but it cannot revert the loss of myocardium and thus provide no curative approach.
The engineering of 3D heart tissues (EHTs) has been developed in 1994 and, in combination with the recent availability of human induced pluripotent stem cells (hiPSCs), may represent a novel, promising technique to treat such cardiac pathologies. EHTs are artificial living and functional 3D heart tissues that could replace injured or malformed heart and restore normal cardiac function on the one hand, and help modeling cardiac diseases and testing drugs in a human heart context on the other hand. However, despite the last years progress and clear advantages compared to 2D cultured hiPSC-cardiomyocytes (CM), EHT-CMs do not reach a fully mature phenotype matching that of isolated CMs from the adult human heart.
Based on preliminary results obtained in the host laboratory, a set of indices suggest a role of CaMKII in the EHT-CMs maturation process. The objective of this proposal is thus to determine whether and, if yes, to which extent different CaMKII isoforms are involved in EHT-CM maturation. The EHT-CaMKII project could have very interesting impact on the EHT-CM maturation enhancement and, consequently, on numerous EHT applications encompassing cardiac repair, drug screening or disease modeling. In addition, it will contribute to understanding the biological role of CaMKII in CM biology.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences biochemistry biomolecules proteins
- natural sciences biological sciences developmental biology
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine cardiology cardiovascular diseases
- medical and health sciences basic medicine pathology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20251 Hamburg
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.